-
-
-
-
-
-
-
Menlo Therapeutics (MNLO) Phase 3 Study MTI-105 and Study MTI-106 did not meet their respective primary endpoint
-
-
-
-
-
-
-
Menlo Therapeutics Provides a Business Update in the Context of COVID-19
-
-
-
-
-
-
-
Menlo Therapeutics (MNLO) Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin Did Not Meet Its Primary Endpoint
-
-
-
-
-
-
-
Foamix and Menlo Announce Shareholder Approval of Proposed Merger
-
-
-
-
-
-
-
UPDATE: Menlo Therapeutics (MNLO) Announces Merger Agreement with Foamix Pharmaceuticals Ltd. (FOMX)
-
-
-
-
-
-
-
Menlo Therapeutics (MNLO) Names Elisabeth Sandoval to Board
-
-
-
-
1,155,254 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

